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Abstract 
For the last 20 years, the “amyloid cascade hypothesis” has dominated research aimed at 
understanding, preventing, and curing Alzheimer’s disease (AD). During that time 
researchers have acquired an enormous amount of data and have been successful, more than 
300 times1, in curing the disease in animal model systems by treatments aimed at clearing 
amyloid deposits. However, to date similar strategies have not been successful in human AD 
patients. Hence, before rushing into further clinical trials with compounds that aim at 
lowering amyloid-beta (Aβ) levels in increasingly younger people, it would be of highest 
priority to re-assess the initial assumption that accumulation of Aβ in the brain is the primary 
pathological event driving AD. Here we question this assumption by highlighting 
experimental evidence in support of the alternative hypothesis suggesting that APP and Aβ 
are part of a neuronal stress/injury system, which is up-regulated to counteract 
inflammation/oxidative stress-associated neurodegeneration that could be triggered by a brain 
injury, chronic infections, or a systemic disease. In AD, this protective program may be 
overridden by genetic and other risk factors, or its maintenance may become dysregulated 
during aging. Here, we provide a hypothetical example of a hypothesis-driven correlation 
between car accidents and airbag release in analogy to the evolution of the amyloid focus and 
as a way to offer a potential explanation for the failure of the AD field to translate the success 
of amyloid-related therapeutic strategies in experimental models to the clinic. 
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Introduction 
At the time of its wording in 1991/92, the “amyloid cascade hypothesis” [1] provided a 
logical explanation for the distinct amyloid-beta (Aβ) plaque pathology in patients diagnosed 
with Alzheimer’s Disease (AD). This hypothesis was supported by the direct link between 
AD and dominant mutations in either the amyloid precursor protein (APP) or enzymes that 
are involved in the production of Aβ peptides, such as presenilin 1 or 2 (PS1/2) [2-5]. 
Subsequently, numerous in vitro studies supported a toxic effect of Aβ peptides and by that 
“approved” its causative role in the disease etiology. However, mice that selectively 
overproduce Aβ peptides (BRI2-Aβ1-42) and develop plaque pathology display no signs of 
progressive cognitive impairments or neurodegeneration [6,7]. In addition, knock-in 
strategies to induce genetic mutations in APP or PS1 in rodents have been proven not to be 
sufficient to evoke AD-like phenotypes [8,9]. The development of certain features of the 
disease in animal models depends on transgene overexpression [10,11] and combinations of 
mutations [12-14]. Only very strong promoters and the presence of multiple mutations in 
mice, a combination never observed in AD patients, triggers most of the neuropathological 
and behavioral phenotypes observed in humans, albeit in very young animals [15]. 
Nevertheless, transgenic-AD animals became state-of-the art tools in the community, and Aβ 
remained the proposed principle toxic and causative agent of the disease; first as monomer, 
then as an insoluble aggregate, followed by a soluble oligomer, and now a combination of all 
of these forms [16-18]. 
Aβ–an acute-phase peptide 
However, despite its proposed toxic/causative role in AD, physiological/protective roles for 
Aβ peptides have been described [19-21]. In addition to these neurotrophic effects of Aβ and 
its neurogenic effect on adult neural stem cells [22], Aβ peptides have been shown to 
stimulate synaptic function at physiological, picomolar, levels [23]. Increases in synaptic 
activity, through NMDA receptor activation, induce Aβ production [24], which at high, 
nanomolar, concentration potently depresses synaptic activity [23]. Hence, Aβ might serve as 
a suitable synaptic guardian against excitotoxicity. Furthermore, Aβ peptides capture metal 
ions such as Zn, Fe, and Cu, potentially reducing oxidative stress to neurons [25]. This is 
consistent with the notion that increased oxidative damage is an early feature in AD 
development [26-29] and with findings that subsequent increases in Aβ accumulation 
correlates with the decrease in oxidative stress [27,30]. Similarly, physiological levels of Aβ 
peptides in plasma and cerebrospinal fluid (CSF) are reported to protect circulating 
lipoproteins from oxidation [31]. 
It has been also demonstrated that Aβ possesses anti-inflammatory [32] and anti-microbial 
function [33]. This potential immune function of Aβ is in line with studies showing that 
induction of APP and Aβ production in brains of non-transgenic mice infected with C. 
pneumonia [34] or Herpes simplex virus type 1 [35]. One should also keep in mind that 
although APP production in the brain is most abundant in neurons, astrocytes also produce 
APP and Aβ and this production is elevated by pro-inflammatory cytokines [36]. 
Interestingly, as has been noted in the brain, stimulation of the peripheral immune system 
induces expression of APP/Aβ in both T-lymphocytes [37] and CD14-positive mononuclear 
phagocytes [38]. Moreover, in humans correlations between neurospirochetosis and AD [39], 
and between periodontal infections and AD [40] are well established. In addition, young 
individuals exposed to elevated air pollution levels show neuroinflammatory responses with a 
significant induction of Aβ1-42 at autopsy [41]. 
Hence, in the context of Alzheimer’s disease progression, Aβ accumulation and plaque 
formation at sites of axonal swellings [42] and leakages [43,44] might be interpreted as the 
brain’s strategy to constrain such inflammation/oxidative stress-inducing hot-spots. This 
hypothesis is well in line with the observation that Aβ plaques form over 24 hours [45], 
possibly as an acute reaction to a burst or leakage of an axon as suggested in [44]. In parallel, 
increases in Aβ or other proteolytic fragments of APP at synaptic sites may act to protect 
vulnerable neurons from glutamate-mediated excitotoxicity [46]. 
APP–a guardian of axonal and synapse integrity 
Important, away from the spot-light of Aβ-driven research, endogenous functions of APP are 
also starting to emerge [47]. Of specific interest are observations in APP knock-out mice, 
which show relatively subtle phenotypes [48] but high vulnerability to mechanical insults and 
low neuroregenerative capacity [49]. The lack of APP expression in these animals is 
associated with enhanced susceptibility to kainic acid-induced epilepsy [50] and elevated 
mortality following cerebral ischemia [51]. These findings are consistent with the idea that 
the observed elevation of APP expression following traumatic brain injury [52-55], entorhinal 
cortex lesion [56], induced ischemia [57-59], systemic infection with a bacterial or a viral 
mimic [60,61], or administration of pro-inflammatory cytokine interleukin 1 [62,63] is a 
protective neuronal response to stress/injury, rather than a pathological event leading to an 
overproduction of Aβ. This is well in line with the notion that while Aβ1-42 levels increase, 
APP levels decrease with advancing AD pathology [64]. In further support of this idea, head 
injury in Drosophila induces an increase in expression of Drosophila APP-Like Protein 
(dAPLP), and mutant flies lacking dAPLP had significantly higher mortality rates after injury 
than wild-type flies [65], suggesting an evolutionarily conserved role of APP in response to 
injury/stress. In rodents, double knock-out of APP and APLP-1 induces severe structural and 
functional synaptic deficits [66], pointing to the crucial role of APP family members in 
synapse development and maintenance. 
Interestingly, a recently discovered “protective” mutation in APP (APPA673T) [67] results not 
only a delay of the onset of AD, but also in better cognitive performance of AD patients that 
carry the mutation. Important, this mutation leads not only to decreases in production of Aβx-
42, but also to a slight increase in levels of secreted APP ectodomain alpha (sAPPα) [67]. This 
is especially interesting as APP expression in aged animals is crucial for induction of long-
term potentiation (LTP) and proper cognitive performance [68] and sAPPα was shown to 
reverse the deficits observed in APP knock-out mice [69]. 
In line with the hypothesis that impairments in axonal integrity and axonal transport represent 
a key contributing factor in the development of AD [44,70], APP has been shown to play a 
role in promoting kinesin-mediated fast axonal transport [71]. In addition, both a lack of APP 
[72] and an increase in proteolytic processing by γ-secretase [73] result in Aβ-independent 
[74] transport deficits. Together these findings suggest that stressful or injurious conditions in 
which APP endogenous functions are compromised, e.g. by a mutation in APP or its 
secretases, axonal transport deficits and subsequent synaptic loss may ensue. This view is 
supported by positron emission tomography (PET) imaging in human subjects in whom white 
matter atrophy and synaptic disconnection were observed early in AD pathogenesis [75-78]. 
Similarly, early white matter atrophy is also observed in women carrying the Apolipoprotein 
E (ApoE) allele ε4 [79], the major genetic risk factor for both familial and sporadic form of 
AD [80]. This is in agreement with the proposed endogenous function of ApoE in neuronal 
response to stress and injury [81,82]. 
Non-demented individuals with AD neuropathology burden 
Interestingly, approximately 25% of cognitively healthy elderly people have Aβ plaque and 
tangle pathology [83], sufficient to meet National Institute on Aging (NIA)-Reagan criteria 
for AD [84-86]. According to the amyloid cascade hypothesis these individuals would have 
developed dementia if they had lived longer, hence the name “prodromal Alzheimer 
patients”. Nevertheless, longitudinal cognitive tests in non-demented individuals above 90 
years of age, but with high AD neuropathology, showed no evidence of cognitive decline 
three years before death [87]. Interestingly, while there was extensive overlap in Aβ peptides 
profile in AD patients and non-demented high pathology individuals [88], the levels of APP 
and Aβ42 were higher in the non-demented group [89]. In agreement with an anti-
inflammatory role of Aβ peptides [32] there was less neuroinflammation in high-pathology 
non-demented individuals [90-92]. In addition, when compared to AD patients, these high-
pathology non-demented individuals showed higher levels of neuroprotective ApoE and 
S100B, as well as angiogenic vascular endothelial growth factor (VEGF) [89]. Such non-
demented individuals may, therefore, be successful in maintaining or recruiting additional 
protective pathways to fight age-associated neuroinflammatory stress [93] and its associated 
neurodegeneration [44]. If so, APP and Aβ may play a significant role in this protection. This 
idea is in line with a transcriptional profiling study, showing that a decisive point in AD 
neuropathogenesis is the induction of stress genes as a reaction of the brain to age-associated 
changes in lipid metabolism and increasing inflammatory stress [94]. 
While targeting inflammatory processes, as suggested by some studies and epidemiological 
data [95,96], may prove efficacious in preventing or delaying the development of AD, these 
treatments failed to show a beneficial effect in patients with symptomatic AD [97]. Hence, in 
order to design therapeutics that would have efficacy in already diagnosed, late-stage, AD 
patients we will have to exploit as yet undiscovered factors or pathways employed by the 
non-demented individuals, who exhibit high levels of neuropatholgical change. In a search 
for such protective factors, a recent genome-wide association study identified three of the top 
ten hits as single-nucleotide polymorphisms (SNPs) in the promoter region of a gene 
encoding for the glycoprotein Reelin [98]. Interestingly, Reelin is an extracellular signaling 
molecule shown to (i) modulate LTP, (ii) be a strong suppressor of Tau 
hyperphosphorylation, and (iii) modulate APP processing (reviewed in [99]). Important, 
compared to age-matched controls, Reelin levels are significantly lower in AD patients 
already at early stages of the disease [100,101], but in high-pathology non-demented 
individuals Reelin production is increased [98]. It was also demonstrated that employing 
histone deacetylase 2 (HDAC) inhibitor following severe experimentally-induced 
neurodegeneration virtually restored brain functionality [102]. This is specifically interesting 
since Reelin promoter is known to be sensitive to epigenetic changes [103]. Therefore, 
exploiting this and similar pathways might be a promising avenue for development of 
treatments for symptomatic AD patients. However, we are afraid that the pursuit of strategies 
other than those directly targeting Aβ may have been hindered by the early and prolonged 
adherence to the Amyloid theory. 
The airbag problem–a hypothetical example 
The idea that the observed increase in Aβ levels as well as Aβ-containing senile plaques in 
AD patients is an adaptive response of the brain to an underlying stress/injury [44,94,104] has 
been put forward by a number of scientists [105-108]. Yet, many researchers continue to treat 
Aβ as the principle etiological agent in AD. While some might argue that an Aβ protective 
versus toxic role depends on the local concentration, it’s aggregation or oligomerization 
status, or the context in which Aβ is produced, we propose here an alternative possibility–
namely that the scientific community is being misled by a seemingly overwhelming amount 
of literature that supports the Aβ hypothesis. 
The rationale for making this strong and provocative statement against the amyloid 
hypothesis is easy to understand if you imagine a scenario in which someone, not knowing 
how a modern car works, is interpreting the significant association of car accidents with the 
presence of released airbags. Based on observations that released airbags are consistently 
observed in crashed cars, but never in intact cars, the airbag became the suspect and possible 
initiating cause of the accidents. Reinforced by the discovery that in a small percentage of car 
accidents (<1%) the spontaneous airbag release, due to a manufacturing defect, actually 
caused the accidence, the engineers design remote-controlled airbags to test the effect of their 
release in moving cars. Not knowing the real purpose of this protective device, the outcome 
and interpretation of this experiment–all performed with state-of-the-art technology, well-
developed and executed strategies, and proper statistics–is absolutely clear: the airbag must 
be the cause. This strong evidence would certainly attract many specialists from different 
fields to investigate the airbag release mechanism in detail. They will eventually succeed, 
perhaps after years of hard work and accumulation of an overwhelming number of scientific 
papers, by changing only one important part of the release mechanism or installation of an 
airbag deployment preventer to hinder the experimentally induced airbag-associated car 
accidents. Since such intervention would prevent even small percentage of accidents caused 
by manufacturing defects that lead to unprovoked airbag deployment, the “airbag hypothesis” 
would become a well-established theory. Nevertheless the production of cars without airbags 
or removal of the airbags from all existing cars would not decrease the number of accidents in 
general-an obvious result if the real purpose of the airbag was known. 
If we translate this hypothetical scenario to AD research, it might provide the explanation for 
the lack of translational success despite tremendous work and money invested in the past 20 
years. We argue here that the overwhelming data produced through the use of transgenic 
overexpression models of AD, which are not suitable for the understanding of the disease 
etiology, led the scientific community down the garden path. We would like to stress here, 
however, that the aim of this alternative view is not to put down the hard work being done by 
the AD-research community, but to encourage “outside the box” thinking toward initiating an 
important discussion and designing of future research directions–beyond Aβ. Finally, 
although we have focused in this article only on APP and Aβ in the context of Alzheimer’s 
disease, the implication of a potential “airbag problem” for bench-to-bedside translational 
efforts is not restricted to research on this protein and its derivatives nor to AD-research only. 
Conclusion 
Alzheimer’s disease (AD) represents one of the major health-issues of modern society with 
no promising treatment on the horizon. A potential problem underlying the failure to treat AD 
in humans is the assumption that senile plaques, the most obvious pathological hallmark of 
the disease, and especially one of the plaque components–Aβ peptide–represent the major 
driving force of the disease. Here, we challenge this view (see the airbag problem) and 
review experimental evidence in support of the hypothesis that APP/Aβ belong to a 
stress/injury-induced protective system of neurons. Hence, we suggest that AD-associated 
mutations in APP as well as PS1/2 impair an endogenous–protective–function of these 
proteins, which will in turn result in elevated neuronal vulnerability, diminution of membrane 
repair following brain injury, and impairments in axonal transport and axonal integrity when 
cellular stress becomes chronic. In the context of late-onset AD, chronic inflammatory stress 
to neurons would, with advancing age, override this protective mechanism leading to the 
same pathological changes as those observed at earlier age in familial AD cases. These 
impairments would–during the course of aging–cause synaptic deterioration, neuronal 
degeneration, and ultimately dementia. In line with this hypothesis and recognized anti-
inflammatory properties of Aβ oligomers, senile plaques may represent an ‘aide de camp’ in 
the neuronal battle against age-associated and inflammation-driven neurodegeneration rather 
than the cause of neuronal cell death. Finally, understanding the protective mechanism(s) in 
cognitively healthy elderly people with high plaque and tangle burden, may hold a key for the 
development of successful treatments for patients already diagnosed with late-onset 
Alzheimer’s disease. 
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